Lilly to Spotlight Growing Hematology Portfolio at 2026 EHA Annual Meeting: Key Data and Strategic Implications
100% citation coverage1 regulatory sources1 peer-reviewed sources
Lilly will present positive Phase 3 BRUIN CLL-322 results at the 2026 EHA Annual Meeting, comparing pirtobrutinib plus venetoclax and rituximab against venetoclax and rituximab. The presentation underscores Lilly's expanding hematology portfolio, bolstered by recent acquisitions of Ajax Therapeutics and Kelonia Therapeutics.
Executive Summary
- Lilly will present positive Phase 3 BRUIN CLL-322 data at EHA 2026 (Stockholm, June 2026), comparing time-limited pirtobrutinib plus venetoclax and rituximab against venetoclax and rituximab alone in CLL/SLL. This is a pivotal confirmatory trial for pirtobrutinib’s accelerated approval in mantle cell lymphoma.
- Lilly is strengthening its hematology pipeline via proposed acquisitions of Ajax Therapeutics (IRAK4 inhibitor AJ1-11095) and Kelonia Therapeutics (gene therapy platform), broadening beyond BTK inhibition into myeloid malignancies and durable gene therapies.
- Jaypirca (pirtobrutinib) already holds FDA accelerated approval for relapsed/refractory MCL after at least two prior lines including a BTK inhibitor, and full approval for CLL/SLL after prior covalent BTK inhibitor therapy. Positive BRUIN CLL-322 data could support full approval for the MCL indication and label expansi
Show 1 more takeaway
- The triplet combination directly takes on standard-of-care regimens from AbbVie (Venclexta) and AstraZeneca (Calquence) by offering a reversible BTK inhibitor backbone with venetoclax and anti-CD20 in a fixed-duration, potentially curative-intent approach.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | high |
| Investment | medium |
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for pirtobrutinib.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Lilly to Spotlight Growing Hematology Portfolio at 2026 EHA Annual Meeting: Key Data and Strategic Implications
Lilly will present positive Phase 3 BRUIN CLL-322 results at the 2026 EHA Annual Meeting, comparing pirtobrutinib plus venetoclax and rituximab against venetoclax and rituximab. The presentation underscores Lilly's expanding hematology portfolio, bolstered by recent acquisitions of Ajax Therapeutics and Kelonia Therapeutics. For BD teams and analysts tracking the BTK-inhibitor wars, this readout provides the first look at a confirmatory trial that could reshape how CLL/SLL patients are treated with time-limited, chemotherapy-free regimens.
Key Takeaways
- Lilly will present positive Phase 3 BRUIN CLL-322 data at EHA 2026 (Stockholm, June 2026), comparing time-limited pirtobrutinib plus venetoclax and rituximab against venetoclax and rituximab alone in CLL/SLL. This is a pivotal confirmatory trial for pirtobrutinib’s accelerated approval in mantle cell lymphoma.
- Lilly is strengthening its hematology pipeline via proposed acquisitions of Ajax Therapeutics (IRAK4 inhibitor AJ1-11095) and Kelonia Therapeutics (gene therapy platform), broadening beyond BTK inhibition into myeloid malignancies and durable gene therapies.
- Jaypirca (pirtobrutinib) already holds FDA accelerated approval for relapsed/refractory MCL after at least two prior lines including a BTK inhibitor, and full approval for CLL/SLL after prior covalent BTK inhibitor therapy. Positive BRUIN CLL-322 data could support full approval for the MCL indication and label expansion into earlier lines.
- The triplet combination directly takes on standard-of-care regimens from AbbVie (Venclexta) and AstraZeneca (Calquence) by offering a reversible BTK inhibitor backbone with venetoclax and anti-CD20 in a fixed-duration, potentially curative-intent approach.
What Changed for Lilly at the 2026 EHA Meeting?
On June 2, 2026, Lilly announced it will spotlight its growing hematology portfolio at the 2026 European Hematology Association (EHA) Annual Meeting. The centerpiece is positive results from the Phase 3 BRUIN CLL-322 study, which randomizes patients with chronic lymphocytic leukemia or small lymphocytic lymphoma to time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab alone. The EHA congress takes place in Stockholm and online, covering the full spectrum of haematology from leukemia to thrombosis. Registration for in-person attendance closes June 14; virtual access runs through June 30. This study is the key confirmatory trial for pirtobrutinib’s accelerated approval in mantle cell lymphoma, originally granted by the FDA based on response rate alone. A full data readout at EHA 2026 will be the first opportunity for regulators, investors, and competitors to assess whether the triplet delivers a clinically meaningful benefit in a randomized setting.
How Does This Data Impact the Competitive Landscape?
The pirtobrutinib-venetoclax-rituximab triplet targets a high-value niche: time-limited, chemotherapy-free therapy for CLL/SLL. Pirtobrutinib is a reversible (non-covalent) BTK inhibitor designed to overcome resistance mutations common with covalent BTK inhibitors like ibrutinib and acalabrutinib. A recent PubMed review notes the expanding role of BTK inhibitors in CLL and the shift from covalent to reversible agents. However, another study cautions about the immunologic paradox of BTK inhibitors, including hypogammaglobulinemia and infection risk. For Lilly, positive BRUIN CLL-322 data would provide a powerful argument for label expansion, enabling direct competition with AbbVie’s Venclexta (venetoclax) and AstraZeneca’s Calquence (acalabrutinib) in the front-line or relapsed setting. The triplet’s time-limited design—fixed-duration therapy—also appeals to patients and payers seeking finite treatment courses, potentially reducing cumulative toxicity and cost. If pirtobrutinib plus venetoclax plus rituximab shows a progression-free survival advantage over venetoclax-rituximab alone, Lilly could file for regulatory approval in the EU and seek full FDA approval for the combination regimen, expanding Jaypirca’s addressable market significantly.
What Are the Strategic Implications for Pharma Teams?
BD and strategy teams should view this readout as a catalyst for Lilly’s broader hematology ambitions. The proposed acquisitions of Ajax Therapeutics (adding AJ1-11095, a novel IRAK4 inhibitor) and Kelonia Therapeutics (a gene therapy platform) signal that Lilly is willing to invest in differentiated mechanisms beyond BTK inhibition to build a durable franchise. For investors and analysts, the EHA 2026 presentation will be the first look at pivotal data that could derisk pirtobrutinib’s confirmatory path and accelerate market uptake. Teams should monitor how the Ajax and Kelonia integrations progress, particularly the clinical entry of AJ1-11095, which could address innate immune-driven hematologic malignancies. The expanding pipeline also positions Lilly to compete with established players like AbbVie in BCL-2 inhibition and BTK inhibition, and with AstraZeneca in reversible BTK inhibitors. The combination of pirtobrutinib with venetoclax and rituximab targets a high-value niche: time-limited therapy in CLL/SLL, potentially challenging standard-of-care regimens. If the data holds up, Lilly could secure a frontline foothold in CLL/SLL, a market currently dominated by BTK inhibitors and BCL-2 combinations.
Frequently Asked Questions
What is the European Haematology Association (EHA)?
The European Hematology Association (EHA) was established in 1992 and serves as a global platform for excellence in hematology, focusing on blood disorders such as leukemia, lymphoma, hemophilia, anemia, and thrombosis. Its annual congress is a major venue for late-breaking clinical data in hematology.
What is pirtobrutinib and why is the BRUIN CLL-322 trial important?
Pirtobrutinib (Jaypirca) is a reversible BTK inhibitor currently approved in the US for relapsed/refractory mantle cell lymphoma under accelerated approval (after at least two prior lines including a BTK inhibitor) and for CLL/SLL after prior covalent BTK inhibitor therapy, per the FDA label. BRUIN CLL-322 is a confirmatory Phase 3 trial testing a time-limited triplet regimen of pirtobrutinib plus venetoclax and rituximab. Positive results could support full approval for the MCL indication and expansion into earlier lines of therapy.
How do the Ajax and Kelonia acquisitions fit into Lilly’s hematology strategy?
The proposed acquisition of Ajax Therapeutics brings AJ1-11095, a novel IRAK4 inhibitor targeting inflammasome and innate immune pathways in myeloid malignancies. The proposed acquisition of Kelonia Therapeutics adds a gene therapy platform aimed at delivering durable, one-time treatments for hematologic disorders. Together, they complement pirtobrutinib and broaden Lilly’s pipeline beyond B-cell malignancies into myeloid and gene therapy spaces.
Sources: PR Newswire – Lilly EHA 2026 announcement | FDA label – Jaypirca and Venclexta | PubMed – From covalent to reversible BTK inhibitors | PubMed – Immunologic paradox of BTK inhibitors
Related profiles
Related coverage
Follow pirtobrutinib developments
Get the latest drug approvals, clinical trials, and regulatory updates delivered to your inbox.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
